862 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval http://www.zacks.com/stock/news/254075/pfizers-immunotherapy-for-skin-cancer-gets-fda-approval?cid=CS-ZC-FT-254075 Mar 24, 2017 - Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.
Merck Closes Acquisition of Controlling Stake in Vallee S.A http://www.zacks.com/stock/news/253862/merck-closes-acquisition-of-controlling-stake-in-vallee-sa?cid=CS-ZC-FT-253862 Mar 23, 2017 - Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.
The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA http://www.zacks.com/stock/news/253495/the-zacks-analyst-blog-highlights-merck-general-electric-mastercard-and-nvidia?cid=CS-ZC-FT-253495 Mar 21, 2017 - The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA
Top Research Reports for Merck, GE and Others http://www.zacks.com/research-daily/106948/top-research-reports-for-merck-ge-and-others?cid=CS-ZC-FT-106948 Mar 20, 2017 - Top Research Reports for Merck, GE and Others
Why Biotech Stock Gilead (GILD) Could Be a Value Trap http://www.zacks.com/stock/news/253363/why-biotech-stock-gilead-gild-could-be-a-value-trap?cid=CS-ZC-FT-253363 Mar 20, 2017 - Gilead's (GILD) valuation looks compelling but is the company really poised for
Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded http://www.zacks.com/stock/news/253183/pharma-stock-roundup-astrazenecas-lynparza-impresses-in-study-merck-drug-label-expanded?cid=CS-ZC-FT-253183 Mar 17, 2017 - Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication http://www.zacks.com/stock/news/252879/mercks-mrk-keytruda-gets-fda-nod-for-lymphoma-indication?cid=CS-ZC-FT-252879 Mar 15, 2017 - Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat http://www.zacks.com/stock/news/252877/celldex-cldx-shares-up-as-q4-loss-narrows-sales-beat?cid=CS-ZC-FT-252877 Mar 15, 2017 - Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays http://www.zacks.com/stock/news/252549/novo-nordisks-diabetes-unit-strong-generic-pressure-stays?cid=CS-ZC-FT-252549 Mar 13, 2017 - We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
How Incyte Stock Became a Bull Market Star for Biotech Investors http://www.zacks.com/stock/news/252365/how-incyte-stock-became-a-bull-market-star-for-biotech-investors?cid=CS-ZC-FT-252365 Mar 10, 2017 - Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

Pages: 1...7778798081828384858687

<<<Page 82>